Sylvester Comprehensive Cancer Center

  • EBV-CTL-302 - Beitinjaneh, Amer

  • Investigator:
    Amer Beitinjaneh
    RCname Email

    Coordinator:

    IRB: 20161025

    SDG: Cellular Therapy
    Disease Site(s):

    Multiple

    Sponsor: Atara

    Enrolling Sites:

    Sylvester

    Title:

    Multicenter, Open Label, Phase 3 Trial of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Solid Organ Transplant (SOT) Patients with EBV-Associated Post Transplant Lymphoproliferative Disease (EBV-PTLD) after Failure of Rituximab or R

    Eligibility Criteria - NCT03394365 *This information has been extracted from " www.clinicaltrials.gov"

  • EA4151 - Beitinjaneh, Amer

  • Investigator:
    Amer Beitinjaneh
    RCname Email

    Coordinator:

    IRB: 20180272

    SDG: Cellular Therapy
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: ECOG

    Enrolling Sites:

    Sylvester

    Title:

    EA4151: A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Co

    Eligibility Criteria - NCT03267433 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230349 - Beitinjaneh Amer

  • Investigator:
    Amer Beitinjaneh
    RCname Email

    Coordinator:

    IRB: 20230349

    SDG: Cellular Therapy
    Disease Site(s):

    Breast,Lung

    Sponsor: Lyell Immunopharma

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Plantation
    Sylvester
    UMH

    Title:

    A Phase 1 Study To Assess The Safety And Efficacy Of LYL797, ROR1-Targeting Car T Cells, In Adults With Relapsed And/Or Refractory Solid Tumor Malignancies

    Eligibility Criteria - NCT05274451 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231360 - Beitinjaneh Amer

  • Investigator:
    Amer Beitinjaneh
    RCname Email

    Coordinator:

    IRB: 20231360

    SDG: Cellular Therapy
    Disease Site(s):

    Hodgkin Lymphoma,Non-Hodgkin Lymphoma

    Sponsor: Indiana University

    Enrolling Sites:

    Coral Springs
    Gables
    Plantation
    Sylvester
    UMH

    Title:

    A Phase I, Multicenter Study of CD4- directed chimeric antigen receptor engineered T-cells (CD4CAR) in patients with Relapsed or Refractory CD4+ Lymphoid Hematological Malignancies

    Eligibility Criteria - NCT03829540 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220984 - Hernandez Aya Leonel

  • Investigator:
    Leonel Hernandez Aya
    RCname Email

    Coordinator:

    IRB: 20220984

    SDG: Cellular Therapy
    Disease Site(s):

    Multiple

    Sponsor: Immatics US Inc

    Enrolling Sites:

    Sylvester

    Title:

    Phase 1/2 study evaluating genetically modified autologous T cells expressing a T-cell receptor recognizing a cancer/germline antigen as monotherapy or in combination with nivolumab in patients with recurrent and/or refractory solid tumors (ACTengine IMA

    Eligibility Criteria - NCT03686124 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231336 - Jimenez Antonio

  • Investigator:
    Antonio Jimenez
    RCname Email

    Coordinator:

    IRB: 20231336

    SDG: Cellular Therapy
    Disease Site(s):

    Leukemia, not otherwise specified,Non-Hodgkin Lymphoma

    Sponsor: NATIONAL MARROW DONOR PROGRAM

    Enrolling Sites:

    Coral Springs
    Gables
    Plantation
    Sylvester
    UMH

    Title:

    A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

    Eligibility Criteria - NCT06001385 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210828 - Lekakis Lazaros

  • Investigator:
    Lazaros Lekakis
    RCname Email

    Coordinator:

    IRB: 20210828

    SDG: Cellular Therapy
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    UMH

    Title:

    ML43165 - Single Arm Phase 2 Trial of an FDA Approved anti-CD19 CAR-T Therapy followed by Mosunetuzumab and Polatuzumab Consolidation for the Treatment of Refractory/Relapsed Aggressive NHL

    Eligibility Criteria - NCT05260957 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231175 - Lekakis Lazaros

  • Investigator:
    Lazaros Lekakis
    RCname Email

    Coordinator:

    IRB: 20231175

    SDG: Cellular Therapy
    Disease Site(s):

    Unknown Sites

    Sponsor: AUTOLUS

    Enrolling Sites:

    Coral Springs
    Plantation
    Sylvester

    Title:

    LONG-TERM FOLLOW-UP OF PATIENTS PREVIOUSLY TREATED WITH AUTOLOGOUS T CELLS GENETICALLY MODIFIED WITH VIRAL VECTORS

    Eligibility Criteria - NCT03628612 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201285 - Pereira Denise

  • Investigator:
    Denise Pereira
    RCname Email

    Coordinator:

    IRB: 20201285

    SDG: Cellular Therapy
    Disease Site(s):

    Multiple Myeloma

    Sponsor: SWOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Hollywood
    Plantation
    Sylvester

    Title:

    S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMAT

    Eligibility Criteria - NCT04071457 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210661 - Pereira Denise

  • Investigator:
    Denise Pereira
    RCname Email

    Coordinator:

    IRB: 20210661

    SDG: Cellular Therapy
    Disease Site(s):

    Multiple Myeloma,Other Hematopoietic

    Sponsor: CELGENE

    Enrolling Sites:

    Sylvester

    Title:

    EXPANDED ACCESS PROTOCOL (EAP) FOR SUBJECTS RECEIVING IDECABTAGENE VICLEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE

    Eligibility Criteria - NCT04771078 *This information has been extracted from " www.clinicaltrials.gov"

  • 20150567 - Ramos Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    Coordinator:

    IRB: 20150567

    SDG: Cellular Therapy
    Disease Site(s):

    Leukemia, Other,Non-Hodgkin Lymphoma

    Sponsor: SCCC

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    A Phase II Trial of Belinostat as Consolidation Therapy with Zidovudine for Adult T-Cell Leukemia-Lymphoma

    Eligibility Criteria - NCT02737046 *This information has been extracted from " www.clinicaltrials.gov"

  • AMC-095 - Ramos, Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    Coordinator:

    IRB: 20160656

    SDG: Cellular Therapy
    Disease Site(s):

    Anus,Lip, Oral Cavity and Pharynx,Lung,Other Hematopoietic

    Sponsor: AMC

    Enrolling Sites:

    Sylvester

    Title:

    A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors

    Eligibility Criteria - NCT02408861 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220755 - Spiegel Jay

  • Investigator:
    Jay Spiegel
    RCname Email

    Coordinator:

    IRB: 20220755

    SDG: Cellular Therapy
    Disease Site(s):

    Multiple

    Sponsor: Kite

    Enrolling Sites:

    Sylvester

    Title:

    Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

    Eligibility Criteria - NCT05041309 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230616 - Spiegel Jay

  • Investigator:
    Jay Spiegel
    RCname Email

    Coordinator:

    IRB: 20230616

    SDG: Cellular Therapy
    Disease Site(s):

    Multiple Myeloma

    Sponsor: Caribou Biosciences

    Enrolling Sites:

    Gables
    Plantation
    Sylvester

    Title:

    A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (CaMMouflage Trial)

    Eligibility Criteria - NCT05722418 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230774 - Spiegel Jay

  • Investigator:
    Jay Spiegel
    RCname Email

    Coordinator:

    IRB: 20230774

    SDG: Cellular Therapy
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: CARGO Therapeutics

    Enrolling Sites:

    Gables
    Plantation
    Sylvester
    UMH

    Title:

    AN OPEN-LABEL, MULTICENTER PHASE 2 STUDY EVALUATING THE EFFICACY AND SAFETY OF CRG-022, A CD22-DIRECTED AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY IN PARTICIPANTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19-DIRECTED CAR T-CELL

    Eligibility Criteria - NCT05972720 *This information has been extracted from " www.clinicaltrials.gov"

  • CCTL019B20031 - Wang, Trent

  • Investigator:
    Trent Wang
    RCname Email

    Coordinator:

    IRB: 20190006

    SDG: Cellular Therapy
    Disease Site(s):

    Lymphoid Leukemia,Non-Hodgkin Lymphoma

    Sponsor: NOVARTIS

    Enrolling Sites:

    Sylvester

    Title:

    CCTL019B2003I: Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or large B-cell lymphoma patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for

    Eligibility Criteria - NCT03601442 *This information has been extracted from " www.clinicaltrials.gov"